Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Ichiro Takemasa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1595-2453; OpenAlex author ID A5027125823, A5029884230. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 12

  1. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.3748/wjg.v31.i32.109383↗
  2. Predictors of occult metastases in potentially Resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.sopen.2024.07.010↗
  3. Conversion pancreaticoduodenectomy with dual arterial reconstructions for locally advanced pancreatic cancer: Case report and literature review. Last author DOI 10.1016/j.ijscr.2021.105692↗
  4. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. Last author DOI 10.3390/cancers13102285↗
  5. Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line. Co-author DOI 10.1007/s00418-019-01821-4↗
  6. Glucose-Dependent FOXM1 Promotes Epithelial-to-Mesenchymal Transition Via Cellular Metabolism and Targeting Snail in Human Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001485↗
  7. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… Last author DOI 10.1002/ags3.12272↗
  8. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Co-author DOI 10.1111/cas.14106↗
  9. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Last author DOI 10.1007/s00262-018-2217-x↗
  10. MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. Co-author DOI 10.1093/carcin/bgx013↗
  11. Serum Metabolite Profiling for the Detection of Pancreatic Cancer: Results of a Large Independent Validation Study. Co-author DOI 10.1097/mpa.0000000000000680↗
  12. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. Co-author DOI 10.1186/1471-2407-13-416↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutoshi Kimura · 10 shared papers, 2017–2025 · strength 1.18
  2. Masafumi Imamura · 8 shared papers, 2018–2025 · strength 1.06
  3. Daisuke Kyuno · 4 shared papers, 2020–2025 · strength 0.55
  4. Makoto Yoshida · 3 shared papers, 2019–2025 · strength 0.49
  5. Takeshi Murakami · 2 shared papers, 2024–2025 · strength 0.41
  6. Masayo Motoya · 3 shared papers, 2017–2025 · strength 0.34
  7. Hiroshi Nakase · 2 shared papers, 2017–2024 · strength 0.26
  8. Takuro Kyuno · 2 shared papers, 2020 · strength 0.22
  9. Takashi Kojima · 2 shared papers, 2020 · strength 0.22
  10. Takumi Konno · 2 shared papers, 2020 · strength 0.22
  11. Tomohiro Kubo · 1 shared paper, 2025 · strength 0.20
  12. Tõru Nakamura · 1 shared paper, 2025 · strength 0.20
  13. Siew‐Kee Low · 1 shared paper, 2025 · strength 0.20
  14. Kazunori Watanabe · 1 shared paper, 2025 · strength 0.20
  15. Yoshihiko Hirohashi · 2 shared papers, 2018–2019 · strength 0.13
  16. Toru Mizuguchi · 2 shared papers, 2018–2019 · strength 0.13
  17. Toshihiko Torigoe · 2 shared papers, 2018–2019 · strength 0.13
  18. Hiroaki Shima · 2 shared papers, 2018–2019 · strength 0.13
  19. Morito Monden · 2 shared papers, 2013–2016 · strength 0.08
  20. Yuichiro Doki · 2 shared papers, 2013–2016 · strength 0.08
  21. Shawn A. Ritchie · 2 shared papers, 2013–2016 · strength 0.08
  22. Hidetoshi Eguchi · 2 shared papers, 2013–2016 · strength 0.08
  23. Hirofumi Akita · 2 shared papers, 2013–2016 · strength 0.08
  24. Hiroaki Nagano · 2 shared papers, 2013–2016 · strength 0.08
  25. Dayan B. Goodenowe · 2 shared papers, 2013–2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.